Laverock Therapeutics appoints new leadership team as it prepares to advance its CAR-T programmes towards clinical development.

Laverock Therapeutics has appointed Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman, as the biotechnology company prepares to advance its lead programmes towards the clinic.
Moss brings experience across cancer genomics, as well as small molecule and RNA drug development and manufacturing. Most recently, he led a $150 million investment in RNA design and manufacturing technology at Wellcome Leap’s R3G programme. He previously held corporate development roles at Exscientia and worked on the cancer programme at Genomics England.
Sekhri brings nearly four decades of life sciences experience and has served on more than 40 public and private company boards. Most recently, he was Chairman of Longboard Pharmaceuticals, overseeing its $2.6 billion acquisition by Lundbeck in December 2024. He is also Chairman, President and CEO of vTv Therapeutics and previously led eGenesis as President and CEO.
The appointments will support Laverock’s transition towards becoming a clinical-stage company, with candidate selection for its ex vivo and in vivo CAR-T programmes expected in the first half of 2027. The company is also planning a Series A financing in 2027.
Commenting on his appointment, Moss said: “My priority is to bring our lead programmes into the clinic. With Paul in New York and our team in the UK, we are well placed to bring together investors and partners on both sides of the Atlantic.”
Sekhri added: “Parker has the scientific depth and partnering experience to take it into the clinic, and I look forward to building the company with him.”
As part of the leadership changes, current CEO David Venables will step down on 31 December following a transition period. Interim Chair Lisa Deschamps will move into a Non-Executive Director role.



No comments yet